Navigation Links
RNC RESPONSE TO OBAMA COMMENTS ON MEDICAL MARIJUANA LAWS
Date:5/14/2008

WASHINGTON, May 14 /PRNewswire-USNewswire/ -- RNC Communications Director Danny Diaz released the following statement today:

"Barack Obama's pledge to stop Executive agencies from implementing laws passed by Congress raises serious doubts about his understanding of what the job of the President of the United States actually is. His refusal to enforce the law reveals that Barack Obama doesn't have the experience necessary to do the job of President, or that he fundamentally lacks the judgment to carry out the most basic functions of the Executive Branch. What other laws would Barack Obama direct federal agents not to enforce?"

OBAMA ON MEDICAL MARIJUANA LAWS

Obama Pledged To Stop DEA Raids On Oregon Medical Marijuana:

Obama Pledged To Stop The Drug Enforcement Administration's Raids On Oregon Medical Marijuana Growers. Willamette Week: "Would you stop the Drug Enforcement Administration's raids on Oregon medical marijuana grows?" Obama: "I would because I think our federal agents have better things to do, like catching criminals and preventing terrorism. The way I want to approach the issue of medical marijuana is to base it on science. And if there is sound science that supports the use of medical marijuana and if it is controlled and prescribed in a way that other medicine is prescribed, then it's something we should consider." (James Pitkin, "Six Minutes With Barack," Willamette Week, 5/14/08)

But The Presidential Oath Of Office Requires The President To "Preserve, Protect And Defend The Constitution Of The United States":

The Presidential Oath Of Office, As Specified In Article II, Section I Of The U.S. Constitution: "I do solemnly swear (or affirm) that I will faithfully execute the Office of the President of the United States, and will to the best of my ability, preserve, protect and defend the Constitution of the United States." (U.S. Department Of State Website,

SOURCE Republican National Committee
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Passport Health Disaster Response Experts Offer Services to Myanmar Volunteers
2. Study identifies molecular response of cartilage to injury
3. Aspen Institute to Release Presidential Candidates Responses to Health Care Reform Questionnaire; New Zogby Poll Findings Also to be Released
4. Previously unseen switch regulates breast cancer response to estrogen
5. CNS Response, Inc.: Poster Session on Referenced-EEG Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting
6. CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board
7. CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference
8. Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response
9. Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria
10. PCMA Response to New York Times Article on Biotech Medicine Costs
11. Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 2Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 3Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:U-M study: Work hassles hamper sleep 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 3Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 4Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 5Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 6Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 7Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 8Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 9Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 10Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 11Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 12Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 13Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 14Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 15Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 16Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 17Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 18Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 19Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 20Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 2Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 3
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7